ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,930.85
      1.09%
      US Tech 100
      20,836.00
      1.31%
      Dow Jones
      42,840.26
      1.18%
      Brent Oil
      72.72
      0.00%
      Bitcoin
      96,609.39
      -0.61%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. USOTC

      6. Daiichi Sankyo Company Ltd (PK) (DSNKY) Quote

      Daiichi Sankyo Company Ltd (PK)

      Daiichi Sankyo Company Ltd (PK) (DSNKY)

      USOTC
      28.15
      0.37
      (1.33%)
      Closed December 21 4:00PM
      Delayed by 15 minutes

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      Key stats and details

      Current Price
      28.15
      Bid
      28.05
      Ask
      28.60
      Volume
      199,126
      26.86 Day's Range 29.27
      26.47 52 Week Range 42.48
      Previous Close
      27.78
      Open
      29.27
      Last Trade
      114
      @
      28.15
      Last Trade Time
      Average Volume (3m)
      124,733
      Financial Volume
      $ 5,642,231
      VWAP
      28.335

      Ask ADVFN Intelligence (AI)

      DSNKY Latest News

      More News

      Apple Loses EU Dispute; Google’s $2.7 Billion Fine Upheld; Oracle Shares Surge 9%

      Apple (NASDAQ:AAPL) – The European Court of Justice ruled against Apple in a tax case regarding benefits received in Ireland, potentially leading to the recovery of up to $14.4 billion in...

      September 10 2024
      IH Market News

      AstraZeneca, Daiichi Sankyo's Enhertu Gets Approval in EU For Lung Cancer Treatment

      By Michael Susin AstraZeneca said that its drug Enhertu, which it developed in partnership with Daiichi Sankyo, has been approved in the European Union for the treatment of advanced non-small cell...

      October 23 2023
      Dow Jones News

      Merck, Daiichi Sankyo Ink Commercialization Deal for Up to $22 Billion

      By Ben Glickman Merck and Daiichi Sankyo agreed to jointly develop and commercialize three potential cancer treatments in a deal worth up to $22 billion. Merck and Daiichi Sankyo will develop and...

      October 19 2023
      Dow Jones News

      AstraZeneca Says Trial Results For Breast Cancer Drug Were Highly Positive

      By Christian Moess Laursen AstraZeneca said trial results for its breast cancer drug Dato-DXd showed significant improvement for the primary end-point of so-called progression-free survival in...

      September 22 2023
      Dow Jones News

      AstraZeneca's Lung-Cancer Treatment Gets Recommended for Approval in the EU

      By Christian Moess Laursen AstraZeneca said its lung-cancer drug Enhertu has been recommended for approval in the European Union following positive test results. The Anglo-Swedish pharma giant...

      September 15 2023
      Dow Jones News

      AstraZeneca Says Datopotamab Deruxtecan Combined With Imfinzi Shows High Disease Control Rates

      By Anthony O. Goriainoff AstraZeneca and Daiichi Sankyo said that datopotamab deruxtecan, a cancer drug, combined with the Imfinzi cancer treatment--with or without chemotherapy--showed disease...

      September 11 2023
      Dow Jones News

      AstraZeneca Says Datopotamab Deruxtecan Phase 3 Trial Shows Positive Results in Lung Cancer Patients

      By Anthony O. Goriainoff AstraZeneca said Monday that its datopotamab deruxtecan treatment showed positive results in patients with advanced non-small cell lung cancer in a clinical Phase 3...

      July 03 2023
      Dow Jones News

      AstraZeneca Cancer Drug Enhertu Shows Clinically Meaningful, Durable Response in Trial

      By Elena Vardon AstraZeneca said Monday that the phase II trial for its cancer drug Enhertu showed clinically meaningful and durable responses across patients with HER2-expressing advanced solid...

      June 05 2023
      Dow Jones News

      AstraZeneca Says Enhertu Recommended for EU Approval for Gastric Cancer

      By Kyle Morris AstraZeneca PLC said Monday that Enhertu has been recommended for approval in the European Union for patients with gastric cancer. The Anglo-Swedish pharma major said...

      November 14 2022
      Dow Jones News

      AstraZeneca, Daiichi's Enhertu Approved by the FDA for Lung Cancer Treatment

      By Michael Susin AstraZeneca PLC and Daiichi Sankyo Co. have said that their antibody drug Enhertu has been approved by the U.S. Food and Drug Administration to treat adult patients with...

      August 12 2022
      Dow Jones News
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10.14990.53535523087428.000129.2726.8642854027.745242DR
      4-0.63-2.1890201528828.7833.2126.8618744728.84242051DR
      12-5.925-17.388114453434.07534.1926.8612473330.24128907DR
      26-6.25-18.168604651234.442.4826.869678932.77232602DR
      521.656.2264150943426.542.4826.4712014232.29154667DR
      1564.1517.29166666672442.4819.3912440930.18552905DR
      260-36.68-56.578744408564.8399.6318.058720930.54273312DR

      DSNKY - Frequently Asked Questions (FAQ)

      What is the current Daiichi Sankyo (PK) share price?
      The current share price of Daiichi Sankyo (PK) is $ 28.15
      What is the 1 year trading range for Daiichi Sankyo (PK) share price?
      Daiichi Sankyo (PK) has traded in the range of $ 26.47 to $ 42.48 during the past year

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      ELIQQElectriq Power Holdings Inc (CE)
      $ 0.10
      (99,900.00%)
      		100
      GNTLFGenetic Technologies Ltd (PK)
      $ 1.00
      (90,809.09%)
      		100
      VIVEViveve Medical Inc (CE)
      $ 0.0003
      (29,900.00%)
      		7.33k
      BTIMBoatim Inc (CE)
      $ 0.0002
      (19,900.00%)
      		799
      CLVRClever Leaves Holdings Inc (CE)
      $ 0.0002
      (19,900.00%)
      		592
      RAASYCloopen Group Holding Limited (CE)
      $ 0.000001
      (-100.00%)
      		214
      EWGFFEat Well Investment Group Inc (CE)
      $ 0.000001
      (-100.00%)
      		47.01k
      SOLBFSoLVBL Solutions Inc (CE)
      $ 0.000001
      (-99.99%)
      		10k
      HAVLFHavn Life Sciences Inc (CE)
      $ 0.000001
      (-99.98%)
      		4.02k
      ENDRFEndor AG (GM)
      $ 0.0001
      (-99.98%)
      		560
      HMBLHUMBL Inc (PK)
      $ 0.00095
      (5.56%)
      		344.89M
      PHILPHI Group Inc (PK)
      $ 0.0003
      (0.00%)
      		312.21M
      PLPLPlandai Biotechnology Inc (PK)
      $ 0.0001
      (0.00%)
      		215.71M
      RDARRaadr Inc (PK)
      $ 0.0014
      (16.67%)
      		174.96M
      CHNVFChina Youzan Ltd (PK)
      $ 0.0177
      (10.63%)
      		100M

      Discussion

      View Full Feed
      carlson carlson 2 minutes ago
      Happy Holidays!!!
      NBRI
      RobotDroid RobotDroid 4 minutes ago
      A fool on a sinking ship.
      NWBO
      blackhawks blackhawks 4 minutes ago
      Trump2 will begin with a deportation and trade war inducing recession that may rival the 'Great One'. If it drags on into '26 the midterms will make Trump not just a lame duck but a dead one.
      Tr8dervic Tr8dervic 5 minutes ago
      Rec'd $25 from Nadine. Thank you!

      ** Current Players (( AND YOUR Number OF PLAYS )) **

      ************************************************************************************************

      Tr8dervic ( 09 ) Plays C5

      ElisGone ( 04 ) Plays C5
      firebag1 firebag1 6 minutes ago
      Yeah I would say this is ready for blast offfffff
      TNXP
      D-Mike D-Mike 7 minutes ago
      Most undervalued stock in the market. We should be $2-$3 bil MC right now ($25 to $35 per share). IMHO
      AVXL
      firebag1 firebag1 7 minutes ago
      That’s fruckking awesome!!!!
      TNXP
      gitreal gitreal 7 minutes ago
      No one referenced "shorty"? Not true. The comment was "One thing for certain, don't believe in Short BS." That tells me that he believes that NBRI is being shorted, and that bashers are just here to support that shorting. Every crappy OTC stock is being shorted massively, right? By evil, corru
      NBRI
      janice shell janice shell 8 minutes ago
      This is how our hero was looking yesterday:

      https://x.com/ronfilipkowski/status/1870587703265513851?s=42

      Seems to have been babbling. Looks as if he forgot his makeup.
      gfp927z gfp927z 9 minutes ago
      Bar, OT - >> S+P 500
      VOO
      BDEZ BDEZ 11 minutes ago
      XRP
      blackhawks blackhawks 11 minutes ago
      What is it going to take for you to comprehend the refutations of what you claim? Recognition Lag can't account for the 'startlingly big difference'. And the rest of the arguments in my posts blow your arguments out of the water.

      Do you really think that the authors are unaware of rec
      BDEZ BDEZ 11 minutes ago
      SHIB
      BDEZ BDEZ 11 minutes ago
      DOGE
      BDEZ BDEZ 11 minutes ago
      BTC
      doc2016 doc2016 11 minutes ago
      news this weekend meta is partnering with oracle cloud to save money?
      maybe zuck talked to some vcsy people or msft about m teams and maybe using ploinks/puddle via 8 versus msft telephony? oracle and netsuite are 8 partners, i've been wondering why now that oracle has their own cloud? or ,
      jtaylor042 jtaylor042 11 minutes ago
      Now take Droid, Marty and Mike with you.
      NWBO
      BDEZ BDEZ 12 minutes ago
      Google announces 10% job cuts in managerial roles, including directors & VP's...
      BDEZ BDEZ 13 minutes ago
      IGEX
      IGEX
      BDEZ BDEZ 13 minutes ago
      LODE
      BDEZ BDEZ 13 minutes ago
      ICTY
      ICTY
      BDEZ BDEZ 13 minutes ago
      WCVC
      BDEZ BDEZ 14 minutes ago
      DPLS
      DPLS

      Your Recent History

      USOTC
      DSNKY
      Daiichi Sankyo (PK)
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads